Core facility for Flow Cytometry UiB/HUS invites **YOU** to a flow-seminar

When: Thursday 23rd October 12.00 – 14.00

Where: Lab building HUS, 9th floor, seminar room

Coffee/tea and wraps are served from 11.45

12.00 – 13.00 MASS CYTOMETRY - CyTOF: Presentation by Fluidigm Corporation.

We are hosting a talk on applications of the CyTOF Mass Cytometer. The CyTOF instrument is being considered for purchase by the core facility. If you would like to learn more about uses of this technology, join us for this presentation.

Mass Cytometry combines the advantages of single cell high speed analysis common to conventional flow cytometry with the ability to resolve over 100 metal probes with minimal signal overlap common to atomic mass spectroscopy.



13.00 – 14.00: **Jorrit Enserink: PhD, Group leader**: Dynamic responses to cell stress, Dept. of Microbiology, Oslo University Hospital.

The decline in drug development efficiency undermines affordable health care – what researchers can do to reverse this trend (using CML as a model disease).

Since the 1950s, the efficiency of research and development (R&D) has declined by 50% each decade. It now costs between $1-2 billion for a company to bring a new drug to the market. Several reasons have been identified for this decline, most of which cannot be influenced by researchers, such as the required number and size of clinical trials, and the drug efficacy standards set by regulatory agencies. However, one aspect that can be influenced by researchers is the efficiency of drug discovery at the hit identification stage. Focusing on chronic myeloid leukemia, we have recently developed a high throughput assay that efficiently filters out toxic compounds with little clinical potential. In my talk I will present this high-throughput drug discovery strategy.

Everybody are most welcome ☺